National and Kapodistrian University of Athens
Μελέτη μικρών συνθετικών μορίων με πιθανή φαρμακολογική δράση: η περίπτωση των κιναζολινών
Abstract
dc:descriptionEGFR can be targeted by three classes of drugs. The first two classes contain molecules which target the extracellular binding domain and are usually either analogues of the epidermal growth factor or monoclonal antibodies raised against the receptor. The other class of drugs contains low molecular weight inhibitors of the tyrosine kinase (TK) activity of EGFR, which target the intracellular ATP binding domain of the receptor. Over the last years several quinazoline derivates have been labeled with short-lived positron emitters, such as 11C, 18F and 124I but, up to now, no labeling has been attempted with 99mTc. The widespread availability of SPECT in comparison with PET technology, the easy production of 99mTc from 99Mo-99mTc generators and the almost ideal properties of 99mTc for SPECT imaging, justify the interest in 99mTc biocomplexes specific for EGFR as an alternative to PET radioligands. In the frames of this Thesis, six new 4-anilinoquinazoline derivatives were studied in vitro. These can be divided into two groups, depending on their substitution at 3- and 4- position of the aniline ring. These groups consist of derivatives bearing 3-Br (first group) or 3-Cl and 4-F (second group). Besides, five complexes of the above quinqzoline derivatives with cold rhenium were studied in vitro. These complexes could be divided into two groups, according to their metal-core. Complexes with the tricarbonyl core fac-(M(CO)3)+ belong to the first group, while the second group contains «4+1» mixed ligand complexes of the general formula MIII(NS3)(CN-R). Both, the quinazoline derivatives and their rhenium complexes were studied in terms of: (1) their ability to inhibit EGFR phosphorylation, (2) type of binding to EGFR (reversible or irreversible), (3) their effect on cell growth, and, (4) their effect on the cell cycle. According to our results, all of the quinazoline derivatives and their rhenium complexes tested retain the quinazoline activity. As it seems, they can cross the cell membrane and act as potent inhibitors of the TK activity of EGFR, while they also inhibit cell growth. Their corresponding IC50 values are well comparable with those of other quinazoline derivatives known from the literature. The incorporation of the rhenium-chelating moiety into the parental quinazoline derivatives did not decrease significantly the activity of the pharmacologically active group, leading to complexes that gave very good in vitro experimental results. In addition, it was shown that complexes with either reversible or irreversible inhibitory activity could be synthesized Among the quinazoline derivatives studied, A1 and A3 (Figure) were found to be the most potent inhibitors of the EGFR phosphorylation (IC50: 17±3.7 nM and 72±3 nM, respectively). Moreover, A3 was shown to bind to EGFR in an irreversible way, to be a potent inhibitor of cell growth (IC50: 2.9±0.3 μM) and to increase the number of cells in the radiation-sensitive G0-G1 phase of the cell cycle. Both A1 and A3 bear Br (3-Br) in their aniline ring (Figure). Among the rhenium complexes studied, Re-A1 (Figure) that contains a bidentate ligand and a fac-(M(CO)3)+ core, and Re-A3 that is based on a «4+1»mixed ligand system, are the most potent inhibitors of EGFR phosphorylation and cell growth. More specifically, Re-A1 that binds to EGFR in a partially reversible way and Re-A3 that binds to EGFR irreversibly, led to similar results in terms of their inhibitory effect on the EGFR phosphorylation (IC50:114±23 nM and 108±13 nM, respectively) and on cell growth (IC50: 2±0.98 μM and 2.9±1.6 μM, respectively). Based on these promising in vitro results, in vivo biodistribution studies have been scheduled, in which 99mTc-labeled complexes will be administered to normal and tumor-bearing mice, in order to evaluate the latter as potential tumor-imaging agents.
Degree
thesis:*- Grantor dc:publisher
- National and Kapodistrian University of Athens
- Year dc:date
- 2009
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Bourkoula, Athanasia
- Μπούρκουλα, Αθανασία
Subjects
dc:subject × 14Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/24225